These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19072367)

  • 1. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease.
    Holbrook K
    J Clin Nurs; 2007 Aug; 16(8):1427-34. PubMed ID: 17655530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive drugs in the treatment of inflammatory bowel disease.
    Aranda R; Horgan K
    Semin Gastrointest Dis; 1998 Jan; 9(1):2-9. PubMed ID: 9547850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies in the thiopurine treatment of inflammatory bowel disease.
    Almer S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):267-77. PubMed ID: 20544506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 8. Review article: monitoring of immunomodulators in inflammatory bowel disease.
    Aberra FN; Lichtenstein GR
    Aliment Pharmacol Ther; 2005 Feb; 21(4):307-19. PubMed ID: 15709982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.
    Ben-Horin S; Goldstein I; Fudim E; Picard O; Yerushalmi Z; Barshack I; Bank I; Goldschmid Y; Meir SB; Mayer L; Chowers Y
    Gut; 2009 Mar; 58(3):396-403. PubMed ID: 18832521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine treatment during lactation.
    Christensen LA; Dahlerup JF; Nielsen MJ; Fallingborg JF; Schmiegelow K
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1209-13. PubMed ID: 18761704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease.
    Atreya R; Atreya I; Neurath MF
    Ann N Y Acad Sci; 2006 Aug; 1072():98-113. PubMed ID: 17057193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
    Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
    Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine and mercaptopurine: lymphoma.
    Prescrire Int; 2011 May; 20(116):126. PubMed ID: 21648178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice.
    Saibeni S; Virgilio T; D'Incà R; Spina L; Bortoli A; Paccagnella M; Peli M; Sablich R; Meucci G; Colombo E; Benedetti G; Girelli CM; Casella G; Grasso G; de Franchis R; Vecchi M
    Dig Liver Dis; 2008 Oct; 40(10):814-20. PubMed ID: 18479986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the delayed onset of action of azathioprine in IBD: are we there yet?
    Atreya I; Neurath MF
    Gut; 2009 Mar; 58(3):325-6. PubMed ID: 19211850
    [No Abstract]   [Full Text] [Related]  

  • 17. Position statement: immunomodulator therapy for inflammatory Bowel disease.
    Lavy A; Chowers Y; Odes HS; Eliakim R;
    Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immunosuppressive agents: Imurel and Purinethol].
    Groupe d'étude thérapeutique des affections inflammatoires digestives
    Rev Prat; 2005 May; 55(9):994. PubMed ID: 16052970
    [No Abstract]   [Full Text] [Related]  

  • 19. Bioequivalence of azathioprine products.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
    van Asseldonk DP; Sanderson J; de Boer NK; Sparrow MP; Lémann M; Ansari A; Almer SH; Florin TH; Gearry RB; Mulder CJ; Mantzaris G; van Bodegraven AA;
    Dig Liver Dis; 2011 Apr; 43(4):270-6. PubMed ID: 20934926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.